Calimmune Approved To Treat Second Group In HIV Stem Cell Gene Modification Study
6/25/2014 9:03:02 AM
SAN DIEGO--(BUSINESS WIRE)--Calimmune, Inc. today announced that encouraging results from a first group of participants indicates the company is ready to begin treating a second cohort in a clinical trial involving the use of Cal-1, an innovative gene-based stem cell therapy to help protect individuals infected with HIV from progressing to AIDS.
Help employers find you! Check out all the jobs and post your resume.
comments powered by